AmbioPharm, Inc.

A global peptide CDMO founded in 2005 and headquartered in North Augusta, South Carolina, specializing in developing highly efficient manufacturing processes for peptide-based APIs at clinical and commercial stages. With manufacturing facilities in South Carolina and Shanghai, China, AmbioPharm produces new chemical entities under cGMP for clients worldwide, with both facilities inspected multiple times by the FDA and other global regulators with excellent outcomes.